Many patients with Crohn disease, an inflammatory bowel disorder, carry mutations in NOD2. The finding that NOD2 normally dampens Toll-like receptor 2–mediated inflammation may explain this association.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hugot, J.P. et al. Nature 411, 599–603 (2001).
Ogura, Y. et al. Nature 411, 503–606 (2001).
Watanabe, T. et al. Nat. Immunol. 5, 800–808 (2004).
Inohara, N. and Nunez, G. Nat. Rev. Immunol. 3, 371–382 (2003).
Ogura, Y. et al. J. Biol. Chem. 276, 4812–4818 (2001).
Inohara, N. et al. J. Biol. Chem. 278, 5509–5512 (2003).
Girardin, S.E. et al. J. Biol. Chem. 278, 8869–8872 (2003).
Girardin, S.E. et al. Science 300, 1584–1587 (2003).
Kobyashi, K. et al. Nature 416, 194–199 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Neill, L. How NOD-ing off leads to Crohn disease. Nat Immunol 5, 776–778 (2004). https://doi.org/10.1038/ni0804-776
Issue Date:
DOI: https://doi.org/10.1038/ni0804-776
This article is cited by
-
What’s new in autoinflammation?
Pediatric Nephrology (2019)
-
Signalling pathways and molecular interactions of NOD1 and NOD2
Nature Reviews Immunology (2006)
-
NOD takes its toll but stays in the CARDs in Crohn’s disease
Journal of Molecular Medicine (2005)
